GSK Set To File Votrient For Ovarian Cancer On Strong PFS
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Votrient demonstrated a 5.6 month PFS improvement compared to placebo in a Phase III ovarian cancer study presented at the ASCO annual meeting, but no overall survival benefit yet. Nevertheless, GSK believes that the risk/benefit profile is good enough now to support filings in the U.S. and Europe.